Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.74 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585275 | 0.85 | ACHE (1.00) | ACHEHTR2ANOS3HTR2CSRD5A1 | |
| SCHEMBL21469199 | 0.82 | ACHE (0.56) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL2484416 | 0.79 | ACHE (0.73) | ACHEHTR2AHTR2BHTR2C | |
| SCHEMBL28857993 | 0.78 | ACHE (0.46) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL22012874 | 0.78 | METAP1 (0.56) | ACHE | |
| SCHEMBL1500072 | 0.78 | METAP1 (0.56) | ACHE | |
| SCHEMBL29404958 | 0.78 | METAP1 (0.56) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL30666881 | 0.78 | ACHE (0.46) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL8696988 | 0.78 | ACHE (0.46) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL10341595 | 0.78 | ACHE (0.56) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479813-B2 | Method of therapeutically treating cancer | ADT PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4053105-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200223816-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| EP-0587107-B1 | Process for the preparation of substituted indanones | HOECHST AG (DE) | 1996-08-14 | — | — | EP | disclosed |
| US-5360936-A | Process for the preparation of substituted indanones | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-01 | — | — | US | disclosed |
| EP-0587107-A1 | Process for the preparation of substituted indanones | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0247724-B1 | THIADIAZINON DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-4861773-A | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-08-29 | — | — | US | disclosed |
| EP-0247724-A1 | Thiadiazinon derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-12-02 | — | — | EP | disclosed |
| US-3970693-A | Process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3953520-A | Chemical compounds and processes | MERCK & CO., INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3944600-A | Indenylidene-3-acetic acid process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | ACHE 982/4885DRD2 1066/4885DRD3 867/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | ACHE 3687/4885DRD2 3948/4885DRD3 3632/4885 |
| US-12479813-B2 | Method of therapeutically treating cancer | RECQL, RDX, RNASE1 | ACHE 1258/4885DRD2 2246/4885DRD3 2333/4885 |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885DRD2 1066/4885DRD3 867/4885 |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885DRD2 1066/4885DRD3 867/4885 |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885DRD2 1066/4885DRD3 867/4885 |
| US-20200223816-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | ACHE 982/4885DRD2 1066/4885DRD3 867/4885 |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885DRD2 1066/4885DRD3 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.